Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
France
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Zaltrap (ziv-aflibercept) is a recombinant fusion protein approved by the FDA, in combination with FOLFIRI (fluorouracil, leucovorin, irinotecan) chemotherapy, for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
Zaltrap is a fusion protein that binds to and neutralizes vascular endothelial growth factor (VEGF-A, VEGF-B) and placental growth factor (PlGF), proteins involved in the formation of new blood vessels that tumors rely on for growth. By blocking this angiogenesis pathway, Zaltrap helps slow tumor growth and spread.
Zaltrap is intended for patients with metastatic colorectal cancer whose disease has progressed despite prior oxaliplatin-based chemotherapy, used in combination with FOLFIRI as a second-line treatment option.
The recommended dose of Zaltrap is 4 mg/kg based on actual body weight, administered as an intravenous infusion over 1 hour, every 2 weeks, in combination with FOLFIRI chemotherapy.
Zaltrap does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Severe and sometimes fatal bleeding events, including gastrointestinal hemorrhage, have been reported. Zaltrap should be discontinued in patients who develop severe bleeding.
Cases of gastrointestinal perforation, sometimes fatal, have occurred. Zaltrap should be permanently discontinued if perforation occurs.
Zaltrap should be suspended prior to elective surgery, and treatment should not be resumed until adequate wound healing has occurred, given the risk of impaired healing and fistula formation.
Severe hypertension and arterial thromboembolic events, including stroke and heart attack, have been reported. Blood pressure should be monitored and controlled during treatment.
RPLS has been reported. Zaltrap should be discontinued if RPLS is confirmed.
Zaltrap may cause fetal harm. Effective contraception should be used during treatment and for a period after the final dose, as advised by the treating physician.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Zaltrap is manufactured and marketed by Sanofi-Aventis. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating oncologist confirming metastatic colorectal cancer diagnosis and prior oxaliplatin-based treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for treatment-experienced metastatic colorectal cancer, Zaltrap is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Zaltrap directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Zaltrap requires refrigerated storage at 2°C to 8°C, protected from light. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Zaltrap through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Zaltrap access.
Delhi's major hospitals assist patients with prescription support and documentation for Zaltrap.
Bangalore's specialist network offers access coordination for eligible colorectal cancer patients seeking Zaltrap.
Chennai-based oncology specialists coordinate Zaltrap access alongside comprehensive colorectal cancer care.
Hyderabad's care institutions support patients pursuing Zaltrap therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Zaltrap.
Pune-based specialists assist with prescription support and Zaltrap treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Zaltrap.
Kochi's specialist units assist patients with the documentation needed for Zaltrap access.
Chandigarh's care centers support Zaltrap treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Zaltrap access process.
Lucknow-based centers assist patients pursuing Zaltrap therapy.
Bhubaneswar's institutions support access to Zaltrap for eligible patients.
Guwahati's specialists help coordinate Zaltrap access for patients across the Northeast.
Patients in other cities across India can also access Zaltrap through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
